Retatrutide (LY3437943) activates GLP-1, GIP, and Glucagon receptors simultaneously — the only triple-mechanism peptide delivering up to 28.7% body weight reduction in Phase 3 data.
Eight concentrations. Every vial HPLC-verified, lyophilized, shipped with batch-specific COA.
Unlike semaglutide (GLP-1 only) or tirzepatide (GLP-1 + GIP), Retatrutide activates three metabolic receptors simultaneously.
Reduces appetite, slows gastric emptying, improves glucose-dependent insulin secretion. The same pathway targeted by semaglutide — amplified by dual co-agonism.
Enhances lipid metabolism, amplifies GLP-1 weight-loss effect. GIP buffers lipid handling and improves insulin sensitivity in adipose tissue.
The key differentiator. Drives lipolysis, increases resting energy expenditure via thermogenesis, achieves >86% liver fat reduction in MASLD substudies.
| Product Name | Retatrutide (Research Grade) |
| CAS Number | 2381089-83-2 |
| Synonym | LY3437943 |
| Molecular Formula | C₂₂₁H₃₄₂N₄₆O₆₈ |
| Molecular Weight | 4,731 g/mol |
| Target Receptors | GIP / GLP-1 / Glucagon (GCG) |
| Purity | ≥99% (HPLC Verified) |
| Form | Lyophilized White Powder |
| Solubility | Sterile or Bacteriostatic Water |
| Endotoxin Level | <1.0 EU/mg |
| Half-life | ~6 days (albumin-bound) |
| Shelf Life | 2 years frozen / 28–30 days at 4°C |
A 39-amino acid synthetic peptide with a GIP-derived backbone modified for Glucagon receptor activity. C20 fatty diacid moiety binds albumin, extending half-life to ~6 days.
Potency hierarchy: highest at GIP (lipid buffering), moderate at GLP-1 (satiety), calibrated at Glucagon (energy expenditure without hyperglycemia).
Published in the New England Journal of Medicine. Ongoing Phase 3: TRIUMPH and TRANSCEND series.
| Parameter | Retatrutide (Triple) | Tirzepatide (Dual) | Semaglutide (Mono) |
|---|---|---|---|
| Mechanism | GIP / GLP-1 / Glucagon | GIP / GLP-1 | GLP-1 only |
| Weight Loss | ~24% – 29% | ~21% | ~15% |
| Liver Fat Reduction | >86% | Moderate | Low |
| Energy Expenditure | ✓ GCG thermogenesis | — | — |
| Receptor Count | ✓✓✓ Triple | ✓✓ Dual | ✓ Mono |
Jastreboff AM et al., NEJM 2023; TRIUMPH-4 (2025); NCT06354660. Research use only.
Third-party verified. Full COA with every batch. C20 fatty acid chain confirmed.
Discreet, sealed packaging shipped worldwide. 24-hour order processing.
QR code on every vial linking to batch Certificate of Analysis.
24-hour order processing. 4–9 day delivery worldwide.
2 years frozen. 28–30 days reconstituted at 4°C.
Pharmacist-assisted protocol design on request.
Subscribe to receive new product announcements, clinical trial updates, and exclusive discounts for subscribers.
Questions about our products, your order, or research protocols? Reach out anytime.
Researchers worldwide trust VitalxLab for pharmaceutical-grade Retatrutide.
Order Now — Free Shipping →